Efficacy and Safety of Dapagliflozin in Children With Proteinuria
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This interventional study investigates the efficacy of dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, in pediatric patients with renal disease. The primary outcomes include changes in 24-hour proteinuria indexed to body surface area (mg/m/day) and glomerular filtration rate (GFR) before and after dapagliflozin administration. By closely monitoring these parameters, the study aims to assess the renal protective potential of dapagliflozin in children and adolescents.